EFSF - eFoodSafety.com Inc - Page 21

If it's up past few days, chances are it will dip back down again. Wait on it and see what it does IMO. But keep doing your dd to see what may be causing it.

EFood...still unsafe

I have traded in and out of this a couple of times, and even with the recent pronouncements of finally moving forward with the DR for the Cinn* products I believe this will continue to be a very high risk stock and will continue to have significant downward pressure at least until it shows some good numbers...they have been making forward looking statements for too long without result to get this to pop on PR and hype alone..JIMHO

You're absolutely right, BigRed, the company is at the point where it has to produce results. If it can do that, there will be a lot of up side. If not, look out below.

Major News; Not Sure If It Will Help

From Yahoo: (note Patricia Gruden is retiring)

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) a leader in the research and development of nutraceutical products today announces that on January 12, 2009 it entered into a definitive share exchange agreement with Freedom2 Holdings, Inc., a worldwide skin care company known for its pioneering development of a permanent and safer, more easily removable tattoo ink.

In a stock for stock exchange, Freedom2’s former shareholders will gain a 20% ownership position in the newly combined entity. Martin Schmieg, the current president and CEO of Freedom2, Inc. will become the Chairman and CEO of eFoodSafety.com, Inc. The company will move its principal executive offices to Freedom2’s current corporate headquarters and manufacturing facility in Cherry Hill, NJ.

“This transaction with Freedom2, signals a new era of growth with a talented management team experienced in healthcare products, research, development, marketing, sales and finance. Freedom2’s highly anticipated consumer product Infinitink™, the more easily removable tattoo ink, positions us for strong future revenues,” said Patricia Gruden, retiring president, chairman and CEO of eFoodSafety.com, Inc.

“This merger offers investors and employees an opportunity to be part of a company aimed at satisfying the growing consumer demand for safer, well-tested alternatives and supplements to protect and enhance their health, beauty and well-being,” said Martin Schmieg, current president and CEO of Freedom2. “Beginning with the launch of Infinitink and the introduction of new products throughout the year, we look forward to a very busy, fruitful 2009.”

Until today, Freedom2 Holdings, Inc. was a privately-held, development stage company, while eFoodSafety.com, Inc. is a public company and files reports and other information with the SEC; its shares are quoted and traded from time to time on the over-the-counter bulletin board under the symbol ”EFSF.” More investor and company information about eFoodSafety is included on the company’s current website www.efoodsafety.com. More background on Freedom2 can be found at its current website www.freedom2inc.com.

I will read from time to time for that. Where i can buy Cinnergen at dis price

NVLX -- New Info From Management

The following is from an interview with NVLX's CEO conducted by The Wall Street Transcript, 1 June 2009:

TWST: What are your priorities for Nuvilex? What will make the next 12 to 24 months successful for the company?

Mr. Schmieg: In a single word, performance. We need to instill a new level of confidence in our investors through performance - setting and achieving our goals. Our initial performance milestone will be in topside revenue growth, which we have given guidance of between $3 million and $5 million for the current fiscal year that runs from May 1, 2009 through April 30, 2010. In the near term, we will be launching our Last Shot Hangover Remedy, a safe and novel blend of essential minerals and nutrients developed to help the body metabolize the sugar in alcohol, thereby preventing or minimizing a hangover. The preventative hangover remedy is packaged in a two-ounce tube and it is meant to be taken in one shot, followed by 16 ounces of water, before going to sleep. Following a successful spring break initiative to market Last Shot along with our InfinitInk, we have seen positive reactions among the key 18 to 25 year-old demographic group. We believe that the product has the potential to make significant revenue contributions.

TWST: Would you give us some insight into your technology platform as well as the lead products that you have under development?

Mr. Schmieg: There are various technology platforms. They include a technology we call P2E, which is an encapsulation technology for developing safe tattoo inks and can also be used for drug delivery. The second is Cinnergen. Cinnergen is our supplement formula that is engineered to help pre-diabetics and diabetics manage their metabolism. Cinnergen has now become a family of products that includes Cinnergen itself; Cinnechol, a supplement to support good cardiovascular health, and two new products. The first is our Last Shot Hangover Remedy, which is a product taken at the end of a night of imbibing and it will eliminate or nearly eliminate all of your hangover symptoms the next morning. The other is Prevorex, an appetite aid to help those who are either on diets or trying to control their calorie intake. Our third technology is Citroxin, which starts as an eco-friendly cleaner that is highly effective as a germicide and antiviral surface cleaner. Citroxin is also being developed as a nematicide and a homeopathic medicine.

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 107 page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .

Can someone change the name of this board to Nuvilex, please?

Nuvilex News on Oraphyte

Currently we have a partner, a multi-billion dollar private agricultural products company, who will be assisting us with the final phases of development and commercialization of Oraphyte for the turf grass industry. We are currently discussing a co-development and commercialization contract for crop protection with a Fortune 100 company. Commercial partners can hasten, through their experience and established market position, product development, introduction and global sales penetration. There is, however, a corresponding cost. If we assume that our partners will bear substantially all of the brand development and distribution costs, our share of the revenues and profits from partnered products will be substantially lower than non-partnered products. We believe, however, for products like Oraphyte maximum market penetration can only be achieved through partnerships with established companies.